Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on April 28, 2023. The report discloses the renewal of employment agreements for two key executives, effective retroactively from January 1, 2023, through January 1, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
The Board of Directors approved the renewal of employment agreements for the following officers:
- Spiro Rombotis (President and CEO):
- Base Salary: $560,131 annually.
- Severance (No Cause): 12 months of base salary plus benefits; 6 months accelerated option vesting.
- Severance (Change in Control): 24 months of base salary plus benefits; 18 months accelerated option vesting; relocation expenses to London.
- Severance (Death/Disability): 12 months of base salary plus benefits; 12 months accelerated option vesting.
- Paul McBarron (EVP-Finance, CFO, COO, Secretary):
- Base Salary: £244,622 annually (GBP).
- Severance (No Cause): 12 months of base salary; 6 months accelerated option vesting.
- Severance (Change in Control): 12 months of base salary; 18 months accelerated option vesting.
- Severance (Death/Disability): 12 months of base salary; 12 months accelerated option vesting.
Both executives are subject to non-competition obligations for one year following termination and are eligible for yearly incentive cash bonuses based on performance criteria.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or general risk factors. The primary contingency disclosed relates to potential future severance liabilities triggered by termination without cause, change in control, death, or disability.
Investor Verification Checklist
- Verify the exact terms of the Employment Agreements by reviewing Exhibits 10.1 and 10.2 attached to the filing.
- Confirm the currency conversion impact of Paul McBarron's salary (GBP) on the company's financial statements.
- Assess the potential cash outflow implications of the severance packages, particularly the 24-month payout for the CEO in a change of control scenario.
- Review the company's current cash position to determine its ability to fund these potential severance obligations.